Normal 0 21 false false false MicrosoftInternetExplorer4
Mosaiques diagnostics GmbH
Further Information : http://www.mosaiques-diagnostics.com
Over the years, Mosaiques has heavily invested R&D and has developed a unique technology on the basis of clinical proteome analysis, enabling the early and differential detection of renal, cardiovascular, and urogenital diseases. In close collaboration with several academic Institutes in Germany and abroad, Mosaiques is currently developing diagnostic tests for additional indications, such as Alzheimer´s disease, pancreatic cancer, and nephrotoxic effects of drugs. Diagnosis is accomplished by highly specific patterns of multiple simultaneously detected biomarkers (proteins/polypeptides) from patient samples obtained in a risk-free and painless procedure. Mosaiques state of the art research in biostatistics/bioinformatics has made possible to efficiently analyze large amounts of data within minutes. This vast wealth of information is expected to facilitate accurate diagnosis of diseases and enable effective therapy prior to serious organ damage.
Petra Zürbig (PhD) received her PhD in Chemistry from the RWTH Aachen in 1997. Between 1998 and 2001 she worked as a postdoctoral fellow on the isolation and characterization of orphan receptor ligands from human hemofiltrate and porcine brain at the Lower Saxony Institute for Peptide Research (IPF), Germany. Here she worked at the department of peptide analysis and achieved deep insight into sequence analysis of peptides via mass spectrometric approaches. She completed her mass spectrometric knowledge as scientist at BioVisioN AG, Germany from 2001-2002. In 2003 she took up the position as head of the proteomics laboratory at the Fraunhofer Institute of Toxicology and Experimental Medicine (ITEM), Germany. Since 2005 she holds the position as group leader of Mosaiques diagnostics GmbH. In addition, she is the project manager of all kidney disease. In addition, she is one of the founding members of the DGPF (German Society of Proteome Research). She is one of 15 authors, who published most papers on clinical proteomics in the last 5 years. With this experience in protein/peptide analyses, she is an expert in the fields of proteomic and peptidomic approaches.
Harald Mischak (PhD) received his PhD from the Technical University of Vienna, Austria, in 1986. After postdoctoral work at the University of Vienna, he was a Fogarty Fellow at the NIH, USA. He continued as Group Leader at the GSF, Munich, Germany from 1993-1998. After one year at the NIDDK, NIH, he took up a position at the Medical School of Hannover in 1999, and founded Mosaiques diagnostics in 2002. Today, he is director of Mosaiques diagnostics and professor of proteomics and Systems Medicine at the University of Glasgow, and a worldwide leading authority in clinical proteome analysis, with more than 200 papers published in peer reviewed journals which have been cited over 13000 times (h-factor 61), and more than 100 patents filed.